Our Mission

Current immunotherapies do not offer therapeutic benefit for most cancer patients.

To overcome these limitations we, a team of scientists at the German Cancer Research Center DKFZ, developed UNIPACT: a novel personalized cell therapy.

UNIPACT combines two proprietary assets to generate a personalised cancer treatment: 

TCR discovery: rapid identification of patient specific tumor killing T cells and their TCR receptors using our proprietary antigen-agnostic IMPACT bioinformatic pipeline 
TCR delivery: our proprietary non-viral, non-integrating nanoSMAR vector that delivers tumor killing TCRs to fresh patient T cells, equipping them to fight their cancer

UNIPACT allows to meet time constraints set by even the most aggressive tumor types. 
In addition, UNIPACT kills tumor cells more effectively and safer than state of the art therapies.

The Team

Tcelltech Founders

Founder, CEO
Prof Dr Michael Platten

Michael is Chairman of the Department of Neurology at the Medical Faculty Mannheim (UMM, part of Heidelberg University), and Professor of Neuroimmunology and Brain Tumor Immunology at the DKFZ. He is consistently rated in the top 1% in his field worldwide. Recently, Michael was awarded the German Cancer Award (alongside BioNTech’s Ugur Sahin) for his achievements in cancer research.

Founder, CSO
Dr Ed Green

Ed is a permanent staff scientist at the DKFZ, and inventor of numerous patents in molecular biology, bioinformatics and high throughput screening that underpin our IMPACT personalised oncology pipeline. Ed’s science has been published extensively in top scientific journals.
Ed’s focus is on scaling up and further developing Tcelltech’s pipelines to reach more patients sooner.

Founder, CTO
Dr Richard Harbottle

Richard leads the DKFZ’s DNA Vector research group, with over two decades experience in the field of gene and cell therapy. Richard is a co- inventor on numerous SMAR technology patents and serves as Tcelltech’s main point of contact to industry, having longstanding collaborations with leading gene therapy companies such as MaxCyte, Lonza and Nature Technologies.


Commercial Co-Founders

Co-Founder, CFO
Dr Mathias Turwitt

Mathias co-founded and led ARCADIA Beteiligungen, a Hamburg-based mid-cap private equity company managing € 370m of assets from international institutional investors over multiple funding rounds. Besides investing in successful Mittelstand companies and being a member of the investment committee, he was also Arcadia’s CFO.

Mathias brings a wealth of experience, especially in business strategy, value creation and fundraising to the Tcelltech team. Within our team, he will focus on securing liquidity, reporting and safeguarding value creation.

Co-Founder, General Counsel
Dr Jochen Dieselhorst

Jochen has been a partner at the international law firm Freshfields Bruckhaus Deringer for +20 years, mainly focusing on international licensing, collaborations and M&A in the biotech and pharma industry. He has led the German healthcare sector group of Freshfields for many years and brings a vast amount of experience in deal-making in the biotech sector.
Jochen’s broad experience and skills have been crucial for Tcelltech in the negotiations of the spin-off from DKFZ. Moving forward, Jochen’s expertise will be critical in leveraging Tcelltech’s IP in license and collaboration agreements.


© 2022 Tcelltech GmbH. All rights reserved.

Responsible Provider in accordance with § 5 of the German Telemedia Act (TMG):

Tcelltech GmbH

Cubex One

Franz-Volhard-Straße 5

68168 Mannheim


T + 49 178 730 730 2





Michael Platten, Richard Harbottle, Edward Green, Mathias Turwitt

Commercial register/register number

District Court of Mannheim HRB 745 600

VAT number 

not yet available